Feasibility of changing for a rechargeable constant current neurostimulator in Parkinson's disease.

Constant Current Stimulation Deep Brain Stimulation Parkinson's Disease Rechargeable Implanted Pulse Generator

Journal

Revue neurologique
ISSN: 0035-3787
Titre abrégé: Rev Neurol (Paris)
Pays: France
ID NLM: 2984779R

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 21 10 2019
revised: 16 02 2020
accepted: 25 02 2020
pubmed: 20 4 2020
medline: 30 7 2021
entrez: 20 4 2020
Statut: ppublish

Résumé

Little is known about outcome and settings adaptations after replacement of constant-voltage non-rechargeable implantable pulse generator (CV-nrIPG) by constant-current rechargeable IPG (CC-rIPG). To determine the feasibility and safety of replacing a CV-nrIPG by a CC-rIPG in Parkinson's disease (PD) and the subsequent outcome. A prospective cohort of thirty PD patients, whose CV-nrIPG was replaced by a CC-rIPG in University Hospital of Lyon between January 2017 and December 2018 (rIPG group) and 39 PD patients, who underwent the replacement of a CV-nrIPG by the same device in 2016 (nrIPG group), were enrolled in this study. Three surgeons performed the operations. Duration of hospitalization for the replacement as well as the number of in or outpatient visits during the first 3 months after the surgery were recorded. In the rIPG group, we compared preoperative DBS settings and the theoretical amplitude estimated using Ohm's law to the amplitude used at the end of follow-up. We assessed patients' and clinicians' opinion on the patient global functioning after the replacement using Clinical Global Impression score. Duration of hospitalization (P=0.47) and need for additional hospitalizations (P=0.73) or consultations (P=0.71) to adapt DBS parameters did not differ between the two groups. Neurological condition (CGI score) was considered as unchanged by both patients and neurologists. Final amplitude of stimulation using CC-rIPG was not predicted by Ohm's law in most cases. Replacing CV-nrIPG by CC-rIPG is safe and well tolerated but require neurological expertise to set the new parameters of stimulation.

Sections du résumé

BACKGROUND BACKGROUND
Little is known about outcome and settings adaptations after replacement of constant-voltage non-rechargeable implantable pulse generator (CV-nrIPG) by constant-current rechargeable IPG (CC-rIPG).
OBJECTIVE OBJECTIVE
To determine the feasibility and safety of replacing a CV-nrIPG by a CC-rIPG in Parkinson's disease (PD) and the subsequent outcome.
METHODS METHODS
A prospective cohort of thirty PD patients, whose CV-nrIPG was replaced by a CC-rIPG in University Hospital of Lyon between January 2017 and December 2018 (rIPG group) and 39 PD patients, who underwent the replacement of a CV-nrIPG by the same device in 2016 (nrIPG group), were enrolled in this study. Three surgeons performed the operations. Duration of hospitalization for the replacement as well as the number of in or outpatient visits during the first 3 months after the surgery were recorded. In the rIPG group, we compared preoperative DBS settings and the theoretical amplitude estimated using Ohm's law to the amplitude used at the end of follow-up. We assessed patients' and clinicians' opinion on the patient global functioning after the replacement using Clinical Global Impression score.
RESULTS RESULTS
Duration of hospitalization (P=0.47) and need for additional hospitalizations (P=0.73) or consultations (P=0.71) to adapt DBS parameters did not differ between the two groups. Neurological condition (CGI score) was considered as unchanged by both patients and neurologists. Final amplitude of stimulation using CC-rIPG was not predicted by Ohm's law in most cases.
CONCLUSIONS CONCLUSIONS
Replacing CV-nrIPG by CC-rIPG is safe and well tolerated but require neurological expertise to set the new parameters of stimulation.

Identifiants

pubmed: 32305140
pii: S0035-3787(20)30509-9
doi: 10.1016/j.neurol.2020.02.007
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

283-289

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

T Wirth (T)

Département de neurologie, hôpital de Hautepierre, hôpitaux universitaires de Strasbourg, Strasbourg, France; Unit of Functional Neurosurgery, National Hospital for Neurology and Neurosurgery, London, United-Kingdom; Inserm-U964/CNRS-UMR7104, institut de génétique et de biologie moléculaire et cellulaire (IGBMC), université de Strasbourg, Illkirch, France.

C Laurencin (C)

Neurologie C, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, Lyon, France; CNRS, UMR 5229, institut des sciences cognitives Marc-Jeannerod, Bron, France. Electronic address: chloe.laurencin@chu-lyon.fr.

J Berthillier (J)

Service de recherche et d'épidémiologie clinique, pôle santé publique, hospices civils de Lyon, Lyon, France.

A Brinzeu (A)

Neurochirurgie A, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, Lyon, France.

G Polo (G)

Neurochirurgie A, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, Lyon, France.

E Simon (E)

Neurochirurgie A, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, Lyon, France; Laboratoire d'anatomie, faculté de médecine Lyon Est, université Claude Bernard Lyon 1, Lyon, France.

P Mertens (P)

Neurochirurgie A, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, Lyon, France; Laboratoire d'anatomie, faculté de médecine Lyon Est, université Claude Bernard Lyon 1, Lyon, France.

E Broussolle (E)

Neurologie C, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, Lyon, France; Univ Lyon, université Lyon 1, faculté de médecine Lyon-Sud, Lyon, France; CNRS, UMR 5229, institut des sciences cognitives Marc-Jeannerod, Bron, France.

T Danaila (T)

Neurologie C, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, Lyon, France; CNRS, UMR 5229, institut des sciences cognitives Marc-Jeannerod, Bron, France.

S Thobois (S)

Neurologie C, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, Lyon, France; Univ Lyon, université Lyon 1, faculté de médecine Lyon-Sud, Lyon, France; CNRS, UMR 5229, institut des sciences cognitives Marc-Jeannerod, Bron, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH